Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The New Political Economy of PharmaceuticalsTRIPS and Access to Medicines in Egypt

The New Political Economy of Pharmaceuticals: TRIPS and Access to Medicines in Egypt [Egypt became fully Trade Related Aspects of Intellectual Property Rights (TRIPS)-compliant in January 2005, when legislation enacted in 2002 came into effect. An adverse impact of TRIPS compliance on the generics drug industry in Egypt was anticipated (EIPR, 2005), but no careful analysis has been undertaken of the effects of changes in intellectual property rights (IPR) legislation. Generics producers, the patent office, the IP Office affiliated with the Ministry of Health (MOH), and experts on pharmaceutical research and development (R&D), however, appear to agree that TRIPS compliance has so far had a negligible impact on domestic generics manufacturers. This is largely the result of the good use made of the transitional period between 1995 and 2005, when drugs registered in this period were exempted from patent protection. There is, to date, little therapeutic demand for drugs newer than those already registered by the MOH. According to the Business Monitor International, ‘a maximum of 16 percent of the medicines available on the Egyptian market are patented’ (BMI, 2009, p. 15). This figure contrasts with other sources that suggest that no more than 5 per cent of drugs are patented (ADE/DOL, 2004, p. 99). But Egypt has been less successful in building R&D capacity in the pharmaceutical sector in preparation for the likely medium- and long-term impacts of TRIPS.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

The New Political Economy of PharmaceuticalsTRIPS and Access to Medicines in Egypt

Part of the International Political Economy Series Book Series
Editors: Löfgren, Hans; Williams, Owain David
Iskander, Dina
The New Political Economy of Pharmaceuticals — Nov 6, 2015
Download PDF
19 pages

Loading next page...
 
/lp/springer-journals/the-new-political-economy-of-pharmaceuticals-trips-and-access-to-2gZbX8WBtx
Publisher
Palgrave Macmillan UK
Copyright
© Palgrave Macmillan, a division of Macmillan Publishers Limited 2013
ISBN
978-1-349-32976-2
Pages
91 –110
DOI
10.1057/9781137315854_5
Publisher site
See Chapter on Publisher Site

Abstract

[Egypt became fully Trade Related Aspects of Intellectual Property Rights (TRIPS)-compliant in January 2005, when legislation enacted in 2002 came into effect. An adverse impact of TRIPS compliance on the generics drug industry in Egypt was anticipated (EIPR, 2005), but no careful analysis has been undertaken of the effects of changes in intellectual property rights (IPR) legislation. Generics producers, the patent office, the IP Office affiliated with the Ministry of Health (MOH), and experts on pharmaceutical research and development (R&D), however, appear to agree that TRIPS compliance has so far had a negligible impact on domestic generics manufacturers. This is largely the result of the good use made of the transitional period between 1995 and 2005, when drugs registered in this period were exempted from patent protection. There is, to date, little therapeutic demand for drugs newer than those already registered by the MOH. According to the Business Monitor International, ‘a maximum of 16 percent of the medicines available on the Egyptian market are patented’ (BMI, 2009, p. 15). This figure contrasts with other sources that suggest that no more than 5 per cent of drugs are patented (ADE/DOL, 2004, p. 99). But Egypt has been less successful in building R&D capacity in the pharmaceutical sector in preparation for the likely medium- and long-term impacts of TRIPS.]

Published: Nov 6, 2015

Keywords: Intellectual Property; Intellectual Property Right; Compulsory Licence; Pharmaceutical Sector; Intellectual Property Right Protection

There are no references for this article.